Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-253 in High Grade Myeloid Malignancies, ALL, Lymphoma, and Solid Tumors
NCT05775406Phase 1Completed
- Sponsor
- Kymera Therapeutics
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of seldegamadlin in Myeloid malignancy, acute lymphoblastic leukemia (ALL), lymphoma and 5 more (2 arms), sponsored by Kymera Therapeutics. Primary endpoints: Incidence and severity of adverse events and Maximum Tolerated Dose (MTD) and recommended Phase 2 dose (RP2D). Started May 2023; status: completed.
02
Drugs
seldegamadlin
03
Conditions
Myeloid malignancyacute lymphoblastic leukemia (ALL)lymphomamyelofibrosis (MF)solid tumor
Beyond the preview
Go deeper on NCT05775406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775406.